TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca PLC announced that as of November 30, 2025, its issued share capital with voting rights consists of 1,550,725,869 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s rules, which could impact shareholder engagement and transparency in the company’s governance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the stock score. The technical analysis suggests potential short-term volatility due to overbought conditions, and the valuation indicates a relatively high price. Despite these concerns, the company’s strategic focus and growth potential support a favorable outlook.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines, focusing on Oncology, Rare Diseases, and BioPharmaceuticals, including areas such as Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are distributed in over 125 countries, serving millions of patients worldwide.
Average Trading Volume: 2,053,879
Technical Sentiment Signal: Buy
Current Market Cap: £216.6B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.